Citations

Institution: Mayo Clinic Clear

Showing 10 of 108135 citations.

Duane K. Rorie, M.D., Ph.D.
Carmichael, Stephen W.

Clinical Anatomy | April 23, 2014 | Volume: 27 | Issue: 6 | Pages: 944-944

10.1002/ca.22408 Get It

Genetic markers of treatment response to tumour necrosis factor-α inhibitors in the treatment of psoriasis
Ryan, Caitriona , Kelleher, John F., Fagan, M. F., Collins, Paul M. , Barker, Juliet N. , Allen, Michael , Hagan, Richard , Renfro, Lindsay A. , Rogers, Simon Neave , Kirby, Brian

Clinical and Experimental Dermatology | April 23, 2014 | Volume: 39 | Issue: 4 | Pages: 519-524

10.1111/ced.12323 | PMID 24758522 Get It

Ly9 (CD229)-Deficient Mice Exhibit T Cell Defects yet Do Not Share Several Phenotypic Characteristics Associated with SLAM- and SAP-Deficient Mice
Graham, Daniel B. , Bell, Michael P., McCausland, Megan, Huntoon, Catherine J., Deursen, Jan van, Faubion, William A. , Crotty, Shane , McKean, D J

The Journal of Immunology | April 23, 2014 | Volume: 176 | Issue: 1 | Pages: 291-300

10.4049/jimmunol.176.1.291 | PMID 16365421 Get It

Abstract Signaling lymphocyte activation molecule (SLAM) family receptors are critically involved in modulating innate and adaptive immune responses. Several SLAM family receptors have been shown to interact with the adaptor molecule SAP; however, subsequent intracellular signaling is poorly defined. Notably, mutations in SLAM-associated protein (SAP) lead to X-linked lymphoproliferative disease, a rare but fatal immunodeficiency. Although the SLAM family member Ly9 (CD229) is known to interact with SAP, the functions of this receptor have remained elusive. Therefore, we have generated Ly9−/− mice and compared their phenotype with that of SLAM−/− and SAP−/− mice. We report that Ly9−/− T cells exhibit a mild Th2 defect associated with reduced IL-4 production after stimulation with anti-TCR and anti-CD28 in vitro. This defect is similar in magnitude to the previously reported Th2 defect in SLAM−/− mice but is more subtle than that observed in SAP−/− mice. In contrast to SLAM−/− and SAP−/− mice, T cells from Ly9−/− mice proliferate poorly and produce little IL-2 after suboptimal stimulation with anti-CD3 in vitro. We have also found that Ly9−/− macrophages exhibit no defects in cytokine production or bacterial killing as was observed in SLAM−/− macrophages. Additionally, Ly9−/− mice differ from SAP−/− mice in that they foster normal development of NKT cells and mount appropriate T and B cell responses to lymphocytic choriomeningitis virus. We have identified significant phenotypic differences between Ly-9−/− mice as compared with both SLAM−/− and SAP−/− mice. Although Ly9, SLAM, and SAP play a common role in promoting Th2 polarization, Ly-9 is uniquely involved in enhancing T cell activation.
Direct Cross-Priming by Th Lymphocytes Generates Memory Cytotoxic T Cell Responses
Kennedy, Richard B. , Undale, Anita H., Kieper, William C., Block, Matthew S. , Pease, Larry R. , Celis, Esteban , Kennedy, Richard

The Journal of Immunology | April 23, 2014 | Volume: 174 | Issue: 7 | Pages: 3967-3977

10.4049/jimmunol.174.7.3967 | PMID 15778353 Get It

Abstract Under optimal Ag stimulation, CTL become functional effector and memory T cells. Professional APCs (pAPC) are considered essential for the activation of CTL, due to their unique capacity to provide costimulation and present exogenous Ags through MHC class I molecules. In this study, we report a novel means by which Th lymphocytes acquire and present MHC class I determinants to naive CTL. Although previous studies have looked at T cell Ag presentation to activated T cells, this study presents the first example of Ag presentation by Th cells to naive CTL. We report that activated Th cells can function as effective pAPC for CTL. Our results show that: 1) In addition to acquisition of cell surface molecules, including MHC class I/peptide complexes, from pAPC, Th cells can acquire and present MHC class I-binding peptides through TCR-MHC class II interactions with pAPC; 2) the acquired Ag can be functionally presented to CTL; and 3) Ag presentation by Th cells induces naive CTL to proliferate and preferentially differentiate into cells that phenotypically and functionally resemble central memory T cells. These findings suggest a novel role of Th cells as pAPC for the development of memory immune responses.
Evaluation of aquaporin‐4 antibody assays
Waters, Patrick , Pittock, Sean J. , Jarius, Sven , Wingerchuk, Dean M., Weinshenker, Brian G. , Bennett, Jeffrey L. , Wingerchuk, Dean M. , Pittock, S J , Waters, Patrick J

Clinical and Experimental Neuroimmunology | April 22, 2014 | Volume: 5 | Issue: 3 | Pages: 290-303

10.1111/cen3.12107 | PMID 27840658 Get It

Abstract Aquaporin‐4 ( AQP 4) is a water channel protein that is most highly, but not exclusively, expressed in the central nervous system. In 2005 AQP 4 was shown to be the antigenic target of neuromyelitis optica‐immunoglobulin G ( NMO ‐IgG, or AQP 4‐IgG), an antibody found specifically in patients with NMO and in formes frustes of NMO , such as longitudinally extensive transverse myelitis (LETM) or optic neuritis (ON). This discovery facilitated the clinical, pathological, and radiological distinction of NMO and the spectrum of NMO ‐related disorders from classical multiple sclerosis. In addition to its use as a diagnostic tool, AQP 4‐IgG predicts a high risk of relapse in patients with a clinically isolated syndrome of either LETM or ON. As disability in NMO is attack‐related, early diagnosis and treatment are predicted to have a major effect on long‐term disability. Thus, the importance of sensitive and specific assays to detect AQP 4‐IgG cannot be overstated. Both academic institutions and commercial companies have developed assays to identify AQP 4‐IgG in patients' sera or cerebrospinal fluid. Both AQP 4 isoforms from different species have been used as the antigenic target in the form of frozen tissue sections in indirect immunofluorescence assays, partially purified protein for fluorescence immunoprecipitation assay, radioimmunoprecipitation assay or enzyme‐linked immunosorbent assay, or transfected into cells for cell based assays or flow cytometry. We carried out a systematic review of the literature reporting different methodologies used to identify AQP 4‐IgG, examine whether longitudinal AQP 4‐IgG titers predict relapses in seropositive patients, and attempt to establish a reasonable timeframe for retesting negative serum samples.
Elimination of Senescent Neutrophils by TNF-Related Apoptosis-Inducing Ligand
Bren, Gary D., McClure, Rebecca F., Badley, Andrew D. , Lum, Julian J. , Badley, Andrew D

The Journal of Immunology | April 22, 2014 | Volume: 175 | Issue: 2 | Pages: 1232-1238

10.4049/jimmunol.175.2.1232 | PMID 16002727 Get It

Abstract Neutrophils are phagocytic effectors which are produced in the bone marrow and released into the circulation. Thereafter, they are either recruited to sites of inflammation or rapidly become senescent, return to the bone marrow, and undergo apoptosis. Stromal cell-derived factor 1 (SDF-1) coordinates the return of senescent neutrophils to the bone marrow by interacting with CXCR4 that is preferentially expressed on senescent neutrophils. We demonstrate that CXCR4 ligation by SDF-1 or other CXCR4 agonists significantly increases the expression of both TNF-related apoptosis-inducing ligand (TRAIL) and of the death-inducing TRAIL receptors on neutrophils, which confers an acquired sensitivity to TRAIL-mediated death and results in TRAIL-dependent apoptosis. In vivo administration of TRAIL antagonists results in neutrophilic accumulation within the bone marrow and a reduction in neutrophil apoptosis; conversely recombinant TRAIL administration reduced neutrophil number within bone marrow. Thus, SDF-1 ligation of CXCR4 causes the parallel processes of chemotaxis and enhanced TRAIL and TRAIL death receptor expression, resulting in apoptosis of senescent neutrophils upon their return to the bone marrow.
Essential Tremor in the Elderly and Risk for Dementia
Shill, Holly A. , Hentz, Joseph G. , Jacobson, Sandra A. , Belden, Christine M. , Beach, Thomas G. , Driver‐Dunckley, Erika , Belden, Christine , Driver-Dunckley, Erika, Sabbagh, Marwan Noel , Adler, Charles H.

Journal of Neurodegenerative Diseases | April 22, 2014 | Volume: 2014 | Issue: No issue available | Pages: 1-5

10.1155/2014/328765 | PMID 26317006 Get It

The objective is to examine the risk of dementia in subjects with essential tremor (ET) involved in the Arizona Study of Aging and Neurodegenerative Disorders. All subjects were free of a neurodegenerative diagnosis at baseline and had annual motor, general neurological, and neuropsychological assessments. Subjects with ET were compared with controls for the risk of dementia. There were 83 subjects with ET and 424 subjects without tremor. Mean age at study entry was 80±5.9 for ET and 76±8.5 for controls. Median tremor duration was 5.2 years at study entry. Followup was a median of 5.4 years (range 0.9 to 12.1). The hazard ratio for the association between ET and dementia was 0.79 (95% CI 0.33 to 1.85). The hazard ratio for the association between tremor onset at age 65 or over, versus onset before age 65, was 2.1 (95% CI 0.24 to 18) and the hazard ratio for the association between tremor duration greater than 5 years, versus less than 5 years, was 0.46 (95% CI 0.08 to 2.6). We conclude that all elderly ET was not associated with an increased risk of dementia but that a subset of subjects with older age onset/shorter duration tremor may be at higher risk.
Cutaneous Injection of Human Subjects with Macrophage Inflammatory Protein-1α Induces Significant Recruitment of Neutrophils and Monocytes
Lee, Sang Chin, Brummet, Mary , Woodworth, Thasia , Leiferman, Kristin M. , Gilman, Steven C., Gladue, Ron P., Schleimer, Robert P. , Shahabuddin, Syed Khurram , Georas, Steve N. , Stellato, Cristiana , Beck, Lisa A.

The Journal of Immunology | April 22, 2014 | Volume: 164 | Issue: 6 | Pages: 3392-3401

10.4049/jimmunol.164.6.3392 | PMID 10706735 Get It

Abstract Macrophage inflammatory protein (MIP-1α), a member of the CC chemokine subfamily, has been shown to attract T cells and monocytes in vitro and to be expressed at sites of inflammation. Although the in vitro activities of MIP-1α have been well documented, the in vivo biological activities of MIP-1α in humans have not been studied. To address this, we challenged human subjects by intradermal injection with up to 1000 pmol of MIP-1α and performed biopsies 2, 10, and 24 h later. Although no acute cutaneous or systemic reactions were noted, endothelial cell activation, as indicated by the expression of E-selectin, was observed. In agreement with its in vitro activity, monocyte, lymphocyte, and, to a lesser degree, eosinophil infiltration was observed, peaking at 10–24 h. Surprisingly, in contrast to its reported lack of in vitro neutrophil-stimulating activity, a rapid infiltration of neutrophils was observed in vivo. This neutrophil infiltration occurred as early as 2 h, preceding the appearance of other cells, and peaked at 10 h. Interestingly, we found that neutrophils in whole blood, but not after isolation, expressed CCR1 on their cell surface. This CCR1 was thought to be functional as assessed by neutrophil CD11b up-regulation following whole-blood MIP-1α stimulation. These studies substantiate the biological effects of MIP-1α on monocytes and lymphocytes and uncover the previously unrecognized activity of MIP-1α to induce neutrophil infiltration and endothelial cell activation, underscoring the need to evaluate chemokines in vivo in humans.
Ovarian and Uterine Cancer Incidence and Mortality in American Indian and Alaska Native Women, United States, 1999–2009
Singh, Simple D., Ryerson, A. Blythe , Wu, Manxia , Kaur, Judith S.

American Journal of Public Health | April 22, 2014 | Volume: 104 | Issue: S3 | Pages: S423-S431

10.2105/ajph.2013.301781 | PMID 24754663 Get It

Objectives. We examined geographic differences and trends in incidence and mortality of ovarian and uterine cancer in American Indian/Alaska Native (AI/AN) women. Methods. We linked mortality data (1990–2009) and incidence data (1999–2009) to Indian Health Service (IHS) records. Death (and incidence) rates for ovarian and uterine cancer were examined for AI/AN and White women; Hispanics were excluded. Analyses focused on Contract Health Service Delivery Area (CHSDA) counties. Results. AI/AN and White women had similar ovarian and uterine cancer death rates. Ovarian and uterine cancer incidence and death rates were higher for AI/ANs residing in CHSDA counties than for all US counties. We also observed geographic differences, regardless of CHSDA residence, in ovarian and uterine cancer incidence and death rates in AI/AN women by IHS region; Pacific Coast and Southern Plains women had higher ovarian cancer death rates and Northern Plains women had higher uterine cancer death rates. Conclusions. Regional differences in the incidence and mortality of ovarian and uterine cancers among AI/AN women in the United States were significant. More research among correctly classified AI/AN women is needed to understand these differences.
Breast Cancer Mortality Among American Indian and Alaska Native Women, 1990–2009
White, Arica , Richardson, Lisa C. , Li, Chunyu , Ekwueme, Donatus U. , Kaur, Judith S.

American Journal of Public Health | April 22, 2014 | Volume: 104 | Issue: S3 | Pages: S432-S438

10.2105/ajph.2013.301720 | PMID 24754658 Get It

Objectives. We compared breast cancer death rates and mortality trends among American Indian/Alaska Native (AI/AN) and White women using data for which racial misclassification was minimized. Methods. We used breast cancer deaths and cases linked to Indian Health Service (IHS) data to calculate age-adjusted rates and 95% confidence intervals (CIs) by IHS-designated regions from 1990 to 2009 for AI/AN and White women; Hispanics were excluded. Mortality-to-incidence ratios (MIR) were calculated for 1999 to 2009 as a proxy for prognosis after diagnosis. Results. Overall, the breast cancer death rate was lower in AI/AN women (21.6 per 100 000) than in White women (26.5). However, rates in AI/ANs were higher than rates in Whites for ages 40 to 49 years in the Alaska region, and ages 65 years and older in the Southern Plains region. White death rates significantly decreased (annual percent change [APC] = −2.1; 95% CI = −2.3, −2.0), but regional and overall AI/AN rates were unchanged (APC = 0.9; 95% CI = 0.1, 1.7). AI/AN women had higher MIRs than White women. Conclusions. There has been no improvement in death rates among AI/AN women. Targeted screening and timely, high-quality treatment are needed to reduce mortality from breast cancer in AI/AN women.